V3-07: POVIDONE IODINE RECTAL PREPARATION AT TIME OF PROSTATE NEEDLE BIOPSY IS A SIMPLE AND REPRODUCIBLE ME

V3-07: POVIDONE IODINE RECTAL PREPARATION AT TIME OF PROSTATE NEEDLE BIOPSY IS A SIMPLE AND REPRODUCIBLE MEANS TO REDUCE RISK OF PROCEDURAL INFECTION

Video

Introductions and Objectives
Single institution and population-based studies highlight that infectious complications following transrectal ultrasound guided prostate needle biopsy (TRUS PNB) are increasing. Such infections are largely attributable to quinolone resistant microorganisms which colonize the rectal vault and are translocated into the bloodstream during the biopsy procedure. A povidone iodine rectal preparation (PIRP) at time of biopsy is a simple, reproducible method to reduced rectal microgranism colony counts and therefore resultant infections following TRUS PNB.

Methods
All patients are administered three days of oral antibiotic therapy prior to biopsy. The PIRP technique involves initially positioning the patient in the standard manner for a TRUS PNB. Following digital rectal examination, 15 mL of a 10% solution of commercially available povidone iodine is mixed with 5 mL of 1% lidocaine jelly to create slurry. A 4cm x 4cm sterile gauze is soaked in this slurry and then inserted into the rectal vault for 2 minutes after which it is removed. Thereafter, a disposable cotton gynecologic swab is used to paint both the perianal area and the rectal vault to a distance of 3cm from the anus. The povidone iodine solution is then allowed to dry for 2-3 minutes prior to proceeding with standard transrectal ultrasonography and subsequent biopsy.

Results
This PIRP technique has been in practice at our institution since March of 2012 with an associated reduction of post-biopsy infections from 4.3% to 0.6% (p = 0.02).

Conclusions
The principal advantage of this prophylaxis regimen is its simplicity and reproducibility with use of an easily available, inexpensive agent to reduce infections. Furthermore, the technique avoids exposing patients to additional systemic antibiotics with potential further propagation of multi-drug resistant organisms. Usage of PIRP at TRUS PNB, however, is not applicable for patients with iodine or shellfish allergies.

Funding: none